Advanced Glycation End Products: Do They Impair Bone Health in
                    Diabetes?

Stella Papachristou; Manfredi Rizzo; Nikolaos Papanas

doi:10.1055/a-1903-1752

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2022; 130(10): 636-637
DOI: 10.1055/a-1903-1752

Editorial

Advanced Glycation End Products: Do They Impair Bone Health in Diabetes?

Authors

Stella Papachristou

¹Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece
Manfredi Rizzo

²Department of Health Promotion Sciences, Maternal and Infantile Care, Internal Medicine and Medical Specialties (Promise), School of Medicine, University of Palermo, Italy
Nikolaos Papanas

¹Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Greece

Abstract

In diabetes mellitus (DM), there is increased formation and accumulation of advanced glycation end products (AGEs), which represent a heterogeneous class of molecules produced by non-enzymatic glycation of various molecules during long-term hyperglycaemia. Several studies have examined the role of AGEs in DM complications. Accumulating evidence suggests that AGEs affect bone metabolism. New knowledge indicates that they may play a role in bone disease among DM subjects. More data are now needed to clarify their role and to explore new AGEs-based therapeutic options for optimal bone health in DM.

Key words

advanced glycation end products - bone formation - complications - diabetes mellitus

Full Text

References

References
1 Ensrud KE, Ewing SK, Taylor BC. et al. Frailty and risk of falls, fracture, and mortality in older women: The study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci 2007; 62: 744-751
2 Johnston CB, Dagar M. Osteoporosis in older adults. Med Clin North Am 2020; 104: 873-884
3 Yamagishi S. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr Drug Targets 2011; 12: 2096-2102
4 Papachristou S, Pafili K, Papanas N. Skin AGEs and diabetic neuropathy. BMC Endocr Disord 2021; 21: 28
5 Twarda-Clapa A, Olczak A, Białkowska AM, Koziołkiewicz M. Advanced glycation end-products (AGEs): Formation, chemistry, classification, receptors, and diseases related to AGEs. Cells 2022; 11: 1312
6 Saito M, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006; 17: 1514-1523
7 Yang X, Liu CJ, Wang ZZ. et al. Effects of advanced glycation end products on osteocytes mechanosensitivity. Biochem Biophys Res Commun 2021; 568: 151-157
8 Jiang J, Zhao C, Han T. et al. Advanced glycation end products, bone health and diabetes mellitus. Exp Clin Endocrinol Diabetes. 2022 in press
9 Zhou Z, Immel D, Xi CX. et al. Regulation of osteoclast function and bone mass by RAGE. J Exp Med 2006; 203: 1067-1080
10 Stirban A, Heinemann L. Skin autofluorescence – a non-invasive measurement for assessing cardiovascular risk and risk of diabetes. Eur Endocrinol 2014; 10: 106-110
11 Smit AJ, Gerrits EG. Skin autofluorescence as a measure of advanced glycation endproduct deposition: A novel risk marker in chronic kidney disease. Curr Opin Nephrol Hypertens 2010; 19: 527-533
12 Sanguineti R, Puddu A, Mach F. et al. Advanced glycation end products play adverse proinflammatory activities in osteoporosis. Mediators Inflamm 2014; 2014: 975872
13 Wang X, Zhao X, Lian T. et al. Skin autofluorescence and the complexity of complications in patients with type 2 diabetes mellitus: A cross-sectional study. BMC Endocr Disord 2021; 21: 58
14 Papachristou S, Pafili K, Trypsianis G. et al. Skin advanced glycation end products among subjects with type 2 diabetes mellitus with or without distal sensorimotor polyneuropathy. J Diabetes Res 2021; 2021: 6045677
15 Papachristou S, Pafili K, Trypsianis G. et al. Correlation between skin advanced glycation end products and cardiac autonomic neuropathy among subjects with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2022; Epub ahead of print. PMID: 35451045
16 Giglio RV, Stoian AP, Haluzik M. et al. Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. Biochim Biophys Acta Mol Basis Dis 2021; 1867: 166148